Home | About us | Editorial board | Ahead of print | Current issue | Archives | Search | Submit article | Instructions | Subscribe | Advertise | Contact us |  Login 
National Journal of Maxillofacial Surgery
 
Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 218
 


 
Table of Contents
EDITORIAL
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 1-2  

Beyond tobacco in head and neck squamous cell cancers… Emerging era of molecular targeted therapy and virtual biopsy


Vice Chancellor, King George’s Medical University, Lucknow, Uttar Pradesh, India

Date of Web Publication26-Oct-2015

Correspondence Address:
Ravi Kant
Vice Chancellor, King George’s Medical University, Lucknow, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0975-5950.168236

Rights and Permissions

How to cite this article:
Kant R. Beyond tobacco in head and neck squamous cell cancers… Emerging era of molecular targeted therapy and virtual biopsy. Natl J Maxillofac Surg 2015;6:1-2

How to cite this URL:
Kant R. Beyond tobacco in head and neck squamous cell cancers… Emerging era of molecular targeted therapy and virtual biopsy. Natl J Maxillofac Surg [serial online] 2015 [cited 2019 Dec 16];6:1-2. Available from: http://www.njms.in/text.asp?2015/6/1/1/168236






Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world, with an annual worldwide incidence of over 600,000 cases/year and 350,000 deaths/year.[1],[2] Despite advances in cancer therapies, 5-year survival rate for oral cancer has remained relatively constant at approximately 50% over the past three decades.[3],[4] This is primarily due to delayed diagnosis, with approximately half of all oral cancers diagnosed at stages III or IV.[5] Historically, HNSCC has been a disease of older males with heavy lifelong tobacco use, high alcohol consumption, poor diet, bad dentition, oral tobacco use, and betel and areca nut chewing, widely prevalent in rural India.[6]

With declining incidence of smoking-related HNSCC, especially in Western countries, newer genetic and viral factors are emerging as determinants of treatment outcome such as human papillomavirus (HPV) status, notably HPV-16, which has emerged as a powerful prognostic indicator, especially in oropharyngeal cancers.[7] HPV-positive patients tend to show favorable prognosis as these patients tend to be younger, healthier, with lower frequency of smoking and alcohol abuse, and also attributable to intrinsic properties of HPV-positive tumor cells, such as increased response to applied therapies, decreased proliferation rate, or an enhanced host immune response toward virus.[8],[9]

E6/E7 viral proteins function as dominant oncoproteins of high-risk HPVs inactivating tumor suppressor proteins, p53 and pRb, and modify cell cycle so as to retain differentiating host keratinocyte in a state that is favorable to amplification of viral genome replication.[10] Viral integration appears to be a requirement for carcinogenesis and significant disruption of host genome at the site of viral integration.[11] In contrast to excellent prognosis of HPV-positive oropharynx cancers, HPV-positive oral and nasopharyngeal cancers may carry worse outcome than HPV-negative cancers arising at these subsites.[12] Furthermore, there seems to be an inverse relationship between epidermal growth factor receptor (EGFR) expression and HPV status.

With the identification of common genetic aberrations and altered signaling pathways in HNSCC, treatment of disease is rapidly evolving with the development of new drugs designed to target crucial receptors and signaling pathways involved in carcinogenesis, enabling us to look beyond cisplatin and taxane-based chemotherapy. Genomic gains and losses of smoking-related HNSCC strongly resemble those in squamous cancers of the lung. Genome-wide sequencing and copy number analysis have clarified commonly mutated genes in HNSCC, such as EGFR, fibroblast growth factor receptor (FGFR), hepatocyte growth factor receptor (c-MET), NOTCH1, MLL2, cyclin D1 (CCND1), or phosphoinositide 3-kinase, with mutation frequencies ranging from 18% to 72%.[13] In non-HPV-related HNSCC, continuous tobacco and alcohol exposure can lead to mutational loss of p16INK4A and p53 genes, detected in 80% of HNSCCs and cause uncontrolled cellular growth. For patients with oral SCC (OSCC), high p16INK4A and low EGFR were associated with improved outcome, suggesting a predictive role in surgically treated patients.[14],[15] CCND1 amplification and overexpression has been identified as an important biomarker to evaluate outcome and treatment response.[16]

Though EGFR overexpression has been observed in approximately 90% of HNSCC tumors and is associated with poor prognosis and resistance to chemotherapy and radiation therapy, disappointingly, only about 10% of HNSCC cases respond to anti-EGFR agents.[17] This has been attributed to mechanisms of resistance to EGFR-targeted therapies. Afatinib, an oral small molecule ErbB family blocker, that irreversibly binds to ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4), is being investigated in HNSCC treatment with encouraging phase II results and several ongoing phase III trials.[18] Besides EGFR inhibitors, inhibitors of FGFR and PIK3CA are all now available with appropriate genetic matching of tumor characteristics with correct inhibitor, a prospective promising area of future research. Thus, next horizon for targeted agents is to find correct combinations of targeted agents for individual tumors based on their genetic profiling.

Principles of tissue autofluorescence, tissue reflectance, or narrow band imaging (NBI) are being used as aids to facilitate early detection of HNSCCs. NBI (Olympus Medical Systems Corporation, Tokyo, Japan) is an endoscopic visualization technology which enhances mucosal surface texture and underlying vasculature by utilizing concept that wavelength of light determines the depth of penetration.[19] Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detecting oral neoplasia with NBI ranged from 95% to 96%, 97–100%, 91–100%, 93–99%, and 97%, respectively. Optical coherence tomography (OCT) is analogous to ultrasound imaging except that it uses light rather than sound. High spatial resolution of OCT enables noninvasive in vivo “optical biopsy” and provides immediate and localized diagnostic information.[20] Confocal endomicroscopy is another noninvasive optical biopsy modality that helps in early diagnosis of oral premalignant lesions. Laser capture microdissection technology based on the extraction of cells from specimens in which exact morphology of both captured cells and surrounding tissue is preserved when combined with rapid immunohistochemical staining techniques help to detect biomarkers and protein fingerprint models facilitating early detection of OSCC.[21] Intensive evaluation of these technologies in prospective clinical trials is needed to find best ways to incorporate them into clinical practice to facilitate early detection of oral malignant lesions leading to improved outcome and survival.

 
   References Top

1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.  Back to cited text no. 1
    
2.
Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis 2014;1:75-86.  Back to cited text no. 2
    
3.
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.  Back to cited text no. 3
    
4.
Brocklehurst P, Kujan O, Glenny AM, Oliver R, Sloan P, Ogden G, et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev 2010;11:CD004150.  Back to cited text no. 4
    
5.
Gómez I, Seoane J, Varela-Centelles P, Diz P, Takkouche B. Is diagnostic delay related to advanced-stage oral cancer? A meta-analysis. Eur J Oral Sci 2009;117:541-6.  Back to cited text no. 5
    
6.
Carey TE, Prince ME. Molecular biology of head and neck cancers. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 10th ed. USA: Lippincott Williams and Wilkins; 2015. p. 416-21.  Back to cited text no. 6
    
7.
Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol 2013;49:560-6.  Back to cited text no. 7
    
8.
Boscolo-Rizzo P, Del Mistro A, Bussu F, Lupato V, Baboci L, Almadori G, et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013;33:77-87.  Back to cited text no. 8
    
9.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens – Part B: Biological agents. Lancet Oncol 2009;10:321-2.  Back to cited text no. 9
    
10.
Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28.  Back to cited text no. 10
    
11.
Hayes N, Consortium T. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2013;517:576-82.  Back to cited text no. 11
    
12.
Duray A, Descamps G, Decaestecker C, Remmelink M, Sirtaine N, Lechien J, et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope 2012;122:1558-65.  Back to cited text no. 12
    
13.
Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 2015;12:11-26.  Back to cited text no. 13
    
14.
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488-92.  Back to cited text no. 14
    
15.
Martinez-Useros J, Garcia-Foncillas J. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncol 2015;51:423-30.  Back to cited text no. 15
    
16.
Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, et al. Biomarkers in advanced larynx cancer. Laryngoscope 2014;124:179-87.  Back to cited text no. 16
    
17.
Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010;15:355-73.  Back to cited text no. 17
    
18.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.  Back to cited text no. 18
    
19.
Gono K, Yamazaki K, Doguchi N, Nonami T, Obi T, Yamaguchi M, et al. Endoscopic observation of tissue by narrowband illumination. Opt Rev 2003;10:211-5.  Back to cited text no. 19
    
20.
Suhr MA, Hopper C, Jones L, George JG, Bown SG, MacRobert AJ. Optical biopsy systems for the diagnosis and monitoring of superficial cancer and precancer. Int J Oral Maxillofac Surg 2000;29:453-7.  Back to cited text no. 20
    
21.
Upile T, Jerjes W, Sterenborg HJ, El-Naggar AK, Sandison A, Witjes MJ, et al. Head and neck optical diagnostics: Vision of the future of surgery. Head Neck Oncol 2009;1:25.  Back to cited text no. 21
    




 

Top
   
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1209    
    Printed41    
    Emailed0    
    PDF Downloaded374    
    Comments [Add]    

Recommend this journal